# Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

> **NCT04441138** · PHASE2 · TERMINATED · sponsor: **Rush University Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Stage III Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04441138
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-25
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Institutional constraints due to research staffing and diminished data safety monitoring infrastructure
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04441138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04441138, "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04441138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*